Objective: This posthoc analysis investigated the relationship between paraoxonase-1 (PON1) genotype and activity, and risk of major adverse cardiovascular events (MACE) and malignancies in clinical studies of tofacitinib in patients with rheumatoid arthritis (RA).
Methods: Data were pooled from 9 phase II/III studies and the associated long-term extension studies (all completed by October 2017). PON1 activities in plasma were measured using paraoxon (paraoxonase activity), dihydrocoumarin (lactonase activity), and phenylacetate (arylesterase activity) as substrates. PON1 Q192R genotype effect on baseline PON1 activity was assessed using linear regression for each study, with fixed-effects metaanalysis across studies. MACE and malignancy risk by time-varying enzyme activity was determined using Cox proportional hazards regression.
Results: The analysis included 1969 patients with RA. Compared with the QQ genotype, the RR genotype had a significant positive association with baseline paraoxonase activity and a significant negative association with baseline lactonase and arylesterase activity (all < 0.001). Time-varying models demonstrated a significant association of increased paraoxonase activity over time with lower risk of MACE ( < 0.001) and malignancies (excluding nonmelanoma skin cancer [NMSC]; ≤ 0.05), even after controlling for risk factors identified in univariate analysis and RA disease activity. A similar trend was observed for lactonase and arylesterase for MACE.
Conclusion: Higher paraoxonase activity over time was associated with significantly reduced risk of future MACE and malignancies (excluding NMSC), but not NMSC, in patients with RA receiving tofacitinib. Further investigation of PON1 as a novel functional lipid biomarker of MACE/malignancy risk in patients with RA is warranted. (ClinicalTrials.gov: NCT01059864, NCT00550446, NCT00687193, NCT00960440, NCT00814307, NCT00856544, NCT00853385, NCT00847613, NCT01039688, NCT00413699, NCT00661661).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.2023-0112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic Characterization of Sarin, Cyclosarin, and Novichoks (A-230, A-232) in Human Liver Microsomes.
Chem Res Toxicol
January 2025
Collaborations Pharmaceuticals, Inc., 1730 Varsity Drivef, Suite 360, Raleigh, North Carolina 27606-5228, United States.
We have assessed the human liver microsomal (HLM) metabolism of the chemical warfare nerve agents' sarin (GB), cyclosarin (GF), and the Novichok agents A-230 and A-232. In HLM, GB showed drastically decreased stability ( = 1.4 h).
View Article and Find Full Text PDFBoswellic acid synergizes with low-dose ionizing radiation to mitigate thioacetamide-induced hepatic encephalopathy in rats.
BMC Pharmacol Toxicol
January 2025
Biochemistry Department, Faculty of Science, Ain-Shams University, Cairo, Egypt.
Hepatic encephalopathy (HE) is a syndrome that arises from acute or chronic liver failure. This study was devised to assess the impact of a combination of boswellic acid (BA) and low doses of gamma radiation (LDR) on thioacetamide (TAA)-induced HE in an animal model. The effect of daily BA treatment (175 mg/kg body weight, for four weeks) and/or fractionated low-dose γ-radiation (LDR; 0.
View Article and Find Full Text PDFDeepening Cisplatin sensitivity on Oral Squamous cell Carcinoma cell lines after PON2 knockdown: A FTIRM investigation.
Spectrochim Acta A Mol Biomol Spectrosc
January 2025
Dipartimento di Scienze Cliniche, Specialistiche ed Odontostomatologiche, Università Politecnica delle Marche, Via Tronto 10/a 60020 Ancona, Italy.
Cisplatin is a platinum-based chemotherapy drug with antimicrobial and antitumoral activity, largely used for a long time in the treatment of several cancers, including the Oral Squamous Cell Carcinoma (OSCC), which is one of the most frequent neoplasms of the oral cavity. Due to its aggressiveness and metastatic invasion, OSCC is characterized by poor outcome, often related also to chemoresistance mechanisms. The intracellular enzyme paraoxonase-2 (PON2) normally acts defending cells from the damages induced by Reactive Oxygen Species.
View Article and Find Full Text PDFSleeve gastrectomy improves HDL function examined by Apo-A1 and atherogenic indices in non-diabetic obese patients.
Cir Cir
January 2025
Department of General Surgery, Antalya Training and Research Hospital, Antalya, Turkey.
Objective: Dysregulation of lipid metabolism can be one of the pathophysiological mechanisms linking high-density lipoprotein cholesterol (HDL-C) dysfunction to obesity. The aim of the study is to show possible changes in lipid metabolism with atherogenic indices in obese patients after sleeve gastrectomy (SG) surgery.
Method: Thirty patients who had SG surgery for obesity were included in the prospective study.
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!